Rosas-Morett MT, Cerda-Contreras KL

Language: Spanish
References: 10
Page: 130-134
PDF size: 327.03 Kb.

ABSTRACT

Alopecia areata is an autoimmune inflammatory disease mediated by T lymphocytes, its first-line treatment includes topical and intralesional corticosteroids. However, its use may be limited in patients with adverse effects secondary to the systemic use of steroids. We present the case of a 74-year-old female patient with recurrent alopecia areata, who developed iatrogenic Cushing’s syndrome and secondary anemia after the use of systemic corticosteroids, which motivated the search for a safe therapeutic alternative. Treatment was initiated with topical 2% crisaborole applied every 12 hours, with complete clinical remission after two months of treatment, without adverse events. This case suggests that crisaborole may represent an effective and safe therapeutic option as a steroid-sparing treatment in patients with alopecia areata and contraindications to the use of corticosteroids.

REFERENCES

1. Rossi A, Muscianese M, Piraccini BM, et al. Alopecia areata:clinical presentation, pathogenesis and therapeutic update.Dermatol Ther. 2023;36(1):e15568.

2. Messenger AG, Senna MM. Alopecia areata: current conceptsand future therapies. Br J Dermatol. 2024;190(3):305–317.

3. Fardet L, Petersen I, Nazareth I. Prevalence and complicationsof systemic glucocorticoid use. Rheumatology (Oxford).2021;60(6):e173–e180.

4. Pincelli C, Schafer P. Mechanisms of phosphodiesterase-4inhibition in inflammatory skin diseases. Exp Dermatol.2023;32(5):623–631.

5. Eichenfield LF, Tom WL, Feldman SR, et al. Topical nonsteroidalanti-inflammatory therapies in dermatology. J Drugs Dermatol.2024;23(2):148–154.

6. Cranwell WC, Lai VWY, Photiou L, et al. Treatment of alopeciaareata: an evidence-based update. Australas J Dermatol.2023;64(4):375–386.

7. ClinicalTrials.gov. A study to evaluate crisaborole topicalointment in subjects with alopecia areata. ClinTrials.govIdentifier: NCT04299503. Última actualización 2024.

8. Zhang Y, Li S, Chen J, et al. Upregulation of phosphodiesterase-4in alopecia areata lesions and its immunologic implications. IntJ Dermatol. 2024;63(8):e512–e518.

9. King B, Guttman-Yassky E, Peeva E, et al. JAK inhibitors foralopecia areata: efficacy, safety, and future directions. J AmAcad Dermatol. 2024;90(1):15–27.

10. Lai VWY, Chen G, Sinclair R. Updated systematic reviewof treatments for alopecia areata. J Am Acad Dermatol.2023;89(4):789–803.